Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2000Expert Opinion on Investigational Drugs

The treatment of psoriasis with IL-10: rationale and review of the first clinical trials

View Full Paper
Ask AI
Bookmark
Share

Authors

KAKhusru AsadullahWDWolf‐Dietrich DöckeRSRobert Sabat

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Asadullah et al. (2000) studied this question.

synapsesocial.com/papers/6a99e2dbc6616c1e40ac012fhttps://doi.org/10.1517/13543784.9.1.95
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interleukin‐10 inhibits IgE‐mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes1995 · 74 citations
  2. 2A PILOT TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-10 IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING OKT3 INDUCTION THERAPY1,21997 · 54 citations
  3. 3IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity.1994 · 196 citations
  4. 4IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 α and STAT3 complexes in human T cells and monocytes1995 · 425 citations